N/A N=55 Progression of Airway Obstruction in Childhood Asthma
Asthma
Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=32 Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
Asthma
Primary: Short-term Lower Leg Growth During Treatment With Flovent Diskus 100 mcg BID or Pulmicort Flexhaler 180 mcg BID. — 0.37; 0.21 mm/wk
Phase 4 N=100 SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)
Asthma
Primary: Number of Participants in Each Arm With a Need for an Increase in Study Medication — 29; 29 Participants
Phase 3 N=465 Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma
Asthma
Primary: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 12 Weeks. — 0.134; 0.293; 0.262 Liter — p=0.0005
Phase 3 N=278 CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)
Asthma
Primary: Rate of Exacerbations Requiring Systemic Corticosteroids — 0.97; 0.95 events per years of follow-up
Phase 3 N=295 Steroids In Eosinophil Negative Asthma
Asthma
Primary: Pairwise Comparison of Treatments Based on Composite Measure Using Treatment Failures, Asthma Control Days, and Percent Predicted FEV1. — 74; 35; 56; 12 Participants…
Phase 3 N=1,771 Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)
Asthma
Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510
Phase 3 N=421 Montelukast in Pediatric Allergic Asthma (0476-336)(COMPLETED)
Asthma
Primary: Percent Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 3 — 9.53; 9.15 Percent Change
Phase 3 N=1,030 Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
Asthma
Primary: Peak FEV1 Within 3 Hours Post-dose Response — 0.075; 0.287; 0.244; 0.252 Litre — p=<0.0001
Phase 2 N=248 Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
Asthma
Primary: Peak Change From Baseline in FEV1 Within 3 Hours Post-dosing on Day 15 — 0.284; 0.261; 0.252; 0.237 Liter
Phase 2 N=578 A Study of Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P04223)
Asthma
Primary: Change From Baseline in Percent Predicted Morning (AM) Forced Expiratory Volume in 1 Second (FEV1) - MF MDI vs. Placebo — 4.52; 6.95; 6.00; 0.66 Percentage of Predicted…
Phase 3 N=78 Study in Adult Patients With Moderate to Severe Asthma
Asthma
Primary: Change From Baseline in Average VAS Score Perceptions of Asthma - Over the Entire 14-day Treatment Period - Question #3 — 2.68; 1.63 score on a scale — p=0.385
Phase 3 N=285 Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
Asthma
Primary: Number of Patients With Drug-related Adverse Events — 3; 6; 10 participants
Phase 4 N=50 Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence
Asthma
Primary: Asthma Control — 1.857; 1.592; 1.792; 1.578 units on a scale — p=0.046
Phase 3 N=746 Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)
Asthma
Primary: Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) — 3.94…
Phase 2 N=68 Symptom Clusters in Children With Exacerbation-prone Asthma
Asthma in Children
Primary: Change in Asthma Control Questionnaire (ACQ) Score — 0.52 score on a scale
Phase 3 N=781 Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)
Asthma
Primary: Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F…
Phase 4 N=257 Treatment Of Symptomatic Asthma In Children
Asthma
Primary: Percentage of Symptom-free Days During the Last 10 Weeks of the Treatment Period — 50.45; 49.75 percentage of days — p=0.63
Phase 2 N=147 Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Asthma
Primary: Change From Baseline in Morning Pre-dose Trough Forced Expiratory Volume in 1 Second (FEV1) at the End of the Treatment Period — -0.002; -0.001; -0.034; -0.031 Liters
Phase 3 N=1,070 Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
Asthma
Primary: Peak FEV1 Within 3 Hours Post-dose Response — 0.053; 0.289; 0.250; 0.266 Litre — p=<0.0001
Phase 2 N=36 A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma
Asthma
Primary: Incidence of Adverse Events — 9; 9; 9; 9 Participants
Phase 2 N=93 Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)
Asthma · Airway Inflammation
Primary: Mean Percent Change From Baseline to Day 14 in Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb) — -35.3; -45.4; -61.4; -51.3 percentage of eNO — p=<0.001
Phase 1 N=27 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma
Asthma
Primary: Number of Participants Who Experienced One or More Adverse Events — 9; 3 Participants
Phase 3 N=459 Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
Asthma
Primary: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. — 0.315; 0.401 Liter — p=0.0110
Phase 3 N=453 Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
Asthma
Primary: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. — 0.248; 0.401 Liter — p=<0.0001
Phase 3 N=1,162 Montelukast Back to School Asthma Study (0476-340)
Asthma
Primary: Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic Participants — 27.23; 24.26 Percentage of Days
Phase 3 N=306 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
Asthma
Primary: Percentage of Participants With First Clinically Significant Exacerbation in Part C — 31.8; 20.2; 49.3; 32.3 Percentage of participants — p=0.004
Phase 3 N=135 Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
Asthma
Primary: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control — 7…
Phase 3 N=689 Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )
Asthma
Primary: Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base Study — 202; 406; 26; 55 Participants
Phase 3 N=300 Individualized Therapy For Asthma in Toddlers
Asthma · Wheezing
Primary: Differential Response to the Three Therapies Based on Fixed Threshold Criteria for the Following Asthma Control Measures: Use of Oral Prednisone for Acute Asthma…